Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869157 | 0.88 | MMP8 (0.56) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL12677382 | 0.86 | MMP8 (0.48) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL28691890 | 0.83 | MMP8 (0.51) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL1645937 | 0.80 | MMP8 (0.51) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL27814580 | 0.80 | SMN1; SMN2 (0.59) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL1646940 | 0.80 | MMP8 (0.51) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL9225532 | 0.80 | MMP8 (0.54) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL11993134 | 0.79 | MMP8 (0.44) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL11971723 | 0.79 | MMP8 (0.44) | MMP8PIN1MEN1NPC1KMT2A | |
| SCHEMBL1904898 | 0.79 | MMP8 (0.44) | MMP8PIN1MEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2014-10-02 | — | — | US | disclosed |
| US-8791273-B2 | 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | JSC GRINDEKS (LV) | 2014-07-29 | — | — | US | disclosed |
| US-8791273-B2 | 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | JSC GRINDEKS (LV) | 2014-07-29 | — | — | US | disclosed |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | MMP8 4476/4885PIN1 2779/4885MEN1 3496/4885 |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | MMP8 4476/4885PIN1 2779/4885MEN1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.